Intrinsic Value of S&P & Nasdaq Contact Us

Cingulate Inc. CING NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
2/6 Pass
SharesGrow Intrinsic Value
$2,260,930.00
+43479323.1%
Analyst Price Target
$11.00
+111.5%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cingulate Inc. (CING) has a negative trailing P/E of -1.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -69.44%, forward earnings yield 22.32%. PEG 0.03 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.03); analyst target implies upside (+111.5%).
  • Forward P/E 4.5 — analysts expect a return to profitability with estimated EPS of $1.16 for FY2029.
  • PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -69.44% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 22.32% as earnings recover.
  • Analyst consensus target $11.00 (+111.5% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 41/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
42/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
94/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
17/100
Debt-to-Equity & liquidity
→ Health
MOAT
28/100
→ Income
GROWTH
15/100
→ Income
INCOME
N/A
No coverage

Valuation Snapshot — CING

Valuation Multiples
P/E (TTM)-1.4
Forward P/E4.5
PEG Ratio0.03
Forward PEG0.03
P/B Ratio12.89
P/S Ratio0.00
EV/EBITDA-1.6
Per Share Data
EPS (TTM)$-4.13
Forward EPS (Est.)$1.16
Book Value / Share$0.46
Revenue / Share$0.00
FCF / Share$2,508.27
Yields & Fair Value
Earnings Yield-69.44%
Forward Earnings Yield22.32%
Dividend Yield0.00%
SharesGrow IV$2,260,930.00 (+43479323.1%)
Analyst Target$11.00 (+111.5%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2019 -130.8 0.00 2,451.43 0.00 -
2020 -210.2 2.22 1,168.17 0.00 -
2021 -45.1 -0.13 44.93 0.00 -
2022 -19.2 0.44 87.40 0.00 -
2023 -8.8 -0.01 -30.24 0.00 -
2024 -1.2 0.01 2.52 0.00 -
2025 -1.0 0.02 9.40 0.00 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $-242.89 $0.00 $-11.45M -
2020 $-154.57 $0.00 $-7.28M -
2021 $-440.14 $0.00 $-20.74M -
2022 $-378.81 $0.00 $-17.85M -
2023 $-311.99 $0.00 $-23.53M -
2024 $-8.80 $0.00 $-15.55M -
2025 $-4.13 $0.00 $-22.45M -

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-1.71 $-3.10 – $-0.06 $2.39M $1.7M – $3.09M 3
2027 $-1.06 $-1.58 – $-0.54 $7.51M $5.01M – $10M 2
2028 $-0.56 $-0.77 – $-0.35 $21.01M $20.39M – $21.63M 1
2029 $1.16 $0.72 – $1.60 $44.12M $31.34M – $56.91M 1
2030 $3.00 $1.87 – $4.13 $70.43M $50.01M – $90.84M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message